Do analysts recommend PSTV or RYM?

Plus Therapeutics currently has a consensus target price of $51.75, indicating a potential upside of 2,791.06%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Plus Therapeutics is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PSTV or RYM more profitable?

RYTHM has a net margin of -6.20% compared to Plus Therapeutics' net margin of -230.24%. RYTHM's return on equity of -12.57% beat Plus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Plus Therapeutics -230.24% -198.48% -73.13% RYTHM -6.20% -12.57% -2.60%

Which has stronger valuation and earnings, PSTV or DWTX?

Plus Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Plus Therapeutics N/A N/A -$22.39M -$2.30 N/A Dogwood Therapeutics N/A N/A -$34.26M -$8.95 N/A

Which has preferable earnings & valuation, GRCE or PSTV?

Grace Therapeutics is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grace Therapeutics N/A N/A -$7.79M -$1.18 N/A Plus Therapeutics N/A N/A -$22.39M -$2.30 N/A

Is SCYX or PSTV more profitable?

SCYNEXIS has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. SCYNEXIS's return on equity of -44.15% beat Plus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets SCYNEXIS N/A -44.15% -32.61% Plus Therapeutics -230.24% -198.48% -73.13%

Do analysts recommend AGFY or PSTV?

Plus Therapeutics has a consensus price target of $51.75, indicating a potential upside of 2,791.06%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Agrify. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is AGFY or PSTV more profitable?

Plus Therapeutics has a net margin of -230.24% compared to Agrify's net margin of -424.11%. Agrify's return on equity of -185.90% beat Plus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Agrify -424.11% -185.90% -72.67% Plus Therapeutics -230.24% -198.48% -73.13%

Plus Therapeutics (PSTV) Competitors

$1.93 +0.14 (+7.82%)

As of 10/9/2026

Compare

PSTV vs. RYM, DWTX, GRCE, SCYX, and AGFY

Should you buy Plus Therapeutics stock or one of its competitors? Plus Therapeutics's main competitors and comparable companies include RYTHM (RYM), Dogwood Therapeutics (DWTX), Grace Therapeutics (GRCE), SCYNEXIS (SCYX), and Agrify (AGFY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Plus Therapeutics compare to RYTHM?

Plus Therapeutics (NASDAQ:PSTV) and RYTHM (NASDAQ:RYM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

RYTHM has a net margin of -6.20% compared to Plus Therapeutics' net margin of -230.24%. RYTHM's return on equity of -12.57% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
RYTHM	-6.20%	-12.57%	-2.60%

Plus Therapeutics currently has a consensus target price of $51.75, indicating a potential upside of 2,791.06%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Plus Therapeutics is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 6.0% of RYTHM shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by company insiders. Comparatively, 3.5% of RYTHM shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, RYTHM had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 1 mentions for RYTHM and 0 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.00 equaled RYTHM'saverage media sentiment score.

Company	Overall Sentiment
Plus Therapeutics	Neutral
RYTHM	Neutral

Plus Therapeutics has higher earnings, but lower revenue than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A
RYTHM	$17.28M	2.66	-$33.26M	-$10.53	N/A

Plus Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, RYTHM has a beta of 9.46, meaning that its share price is 846% more volatile than the broader market.

Summary

RYTHM beats Plus Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Plus Therapeutics compare to Dogwood Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Plus Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A

In the previous week, Dogwood Therapeutics had 4 more articles in the media than Plus Therapeutics. MarketBeat recorded 4 mentions for Dogwood Therapeutics and 0 mentions for Plus Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.25 beat Plus Therapeutics' score of 0.00 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Plus Therapeutics	Neutral
Dogwood Therapeutics	Neutral

Dogwood Therapeutics has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Dogwood Therapeutics' return on equity of -75.55% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Dogwood Therapeutics	N/A	-75.55%	-40.28%

Plus Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

Plus Therapeutics presently has a consensus target price of $51.75, suggesting a potential upside of 2,791.06%. Dogwood Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 757.14%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Plus Therapeutics is more favorable than Dogwood Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Dogwood Therapeutics beats Plus Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Plus Therapeutics compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Grace Therapeutics has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Grace Therapeutics' return on equity of -36.11% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-36.11%	-34.39%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Grace Therapeutics is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

Grace Therapeutics has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 10.8% of Grace Therapeutics shares are held by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Grace Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 188.46%. Plus Therapeutics has a consensus price target of $51.75, indicating a potential upside of 2,791.06%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Grace Therapeutics had 2 more articles in the media than Plus Therapeutics. MarketBeat recorded 2 mentions for Grace Therapeutics and 0 mentions for Plus Therapeutics. Grace Therapeutics' average media sentiment score of 0.91 beat Plus Therapeutics' score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Grace Therapeutics	Positive
Plus Therapeutics	Neutral

Summary

Grace Therapeutics beats Plus Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Plus Therapeutics compare to SCYNEXIS?

SCYNEXIS (NASDAQ:SCYX) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

In the previous week, SCYNEXIS had 8 more articles in the media than Plus Therapeutics. MarketBeat recorded 8 mentions for SCYNEXIS and 0 mentions for Plus Therapeutics. SCYNEXIS's average media sentiment score of 0.82 beat Plus Therapeutics' score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Overall Sentiment
SCYNEXIS	Positive
Plus Therapeutics	Neutral

54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 4.1% of SCYNEXIS shares are held by insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

SCYNEXIS has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

SCYNEXIS currently has a consensus price target of $33.00, indicating a potential upside of 708.82%. Plus Therapeutics has a consensus price target of $51.75, indicating a potential upside of 2,791.06%. Given Plus Therapeutics' higher probable upside, analysts plainly believe Plus Therapeutics is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

SCYNEXIS has higher revenue and earnings than Plus Therapeutics. SCYNEXIS is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	1.97	-$8.61M	-$2.09	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

SCYNEXIS has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. SCYNEXIS's return on equity of -44.15% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	N/A	-44.15%	-32.61%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Summary

SCYNEXIS beats Plus Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Plus Therapeutics compare to Agrify?

Agrify (NASDAQ:AGFY) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Agrify has a beta of 9.96, indicating that its stock price is 896% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

In the previous week, Agrify's average media sentiment score of 0.00 equaled Plus Therapeutics'average media sentiment score.

Company	Overall Sentiment
Agrify	Neutral
Plus Therapeutics	Neutral

6.0% of Agrify shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 2.2% of Agrify shares are owned by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Plus Therapeutics has a net margin of -230.24% compared to Agrify's net margin of -424.11%. Agrify's return on equity of -185.90% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agrify	-424.11%	-185.90%	-72.67%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Plus Therapeutics has a consensus price target of $51.75, indicating a potential upside of 2,791.06%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Agrify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Plus Therapeutics has lower revenue, but higher earnings than Agrify. Agrify is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agrify	$12.26M	3.19	-$41.75M	-$22.65	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

Summary

Plus Therapeutics beats Agrify on 8 of the 13 factors compared between the two stocks.

Get Plus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PSTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PSTV vs. The Competition

Export

Metric	Plus Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.29M	$12.42B	$7.26B	$13.30B
Dividend Yield	N/A	2.63%	2.52%	22.58%
P/E Ratio	-0.84	636.89	201.60	20.20
Price / Sales	N/A	746.40	581.89	87.91
Price / Cash	N/A	86.66	76.96	53.71
Price / Book	2.68	10.71	11.22	6.33
Net Income	-$22.39M	$2.84B	$3.50B	$382.15M
7 Day Performance	20.63%	-0.94%	-0.89%	-1.40%
1 Month Performance	-22.49%	-4.89%	-4.42%	-3.47%
1 Year Performance	-88.94%	-4.12%	7.03%	1.18%

Plus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PSTV Plus Therapeutics	N/A	$1.93 +7.8%	$51.75 +2,581.3%	-90.1%	$13.29M	N/A	N/A	20
RYM RYTHM	0.8449 of 5 stars	$20.90 -3.9%	N/A	-54.1%	$47.42M	$17.28M	N/A	141	Positive News
DWTX Dogwood Therapeutics	3.3152 of 5 stars	$1.36 flat	$12.00 +782.4%	-75.0%	$46.23M	N/A	N/A	8	News Coverage Short Interest Decrease Gap Up
GRCE Grace Therapeutics	2.1506 of 5 stars	$2.12 flat	$6.00 +183.0%	-31.1%	$44.60M	N/A	N/A	5	Positive News
SCYX SCYNEXIS	3.197 of 5 stars	$4.62 +5.2%	$33.00 +614.3%	-35.6%	$43.68M	$20.60M	N/A	29	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PSTV) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Plus Therapeutics (PSTV) Competitors

PSTV vs. RYM, DWTX, GRCE, SCYX, and AGFY

How does Plus Therapeutics compare to RYTHM?

Summary

How does Plus Therapeutics compare to Dogwood Therapeutics?

Summary

How does Plus Therapeutics compare to Grace Therapeutics?

Summary

How does Plus Therapeutics compare to SCYNEXIS?

Summary

How does Plus Therapeutics compare to Agrify?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTV vs. The Competition

Plus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Plus Therapeutics (PSTV) Competitors

PSTV vs. RYM, DWTX, GRCE, SCYX, and AGFY

How does Plus Therapeutics compare to RYTHM?

Is PSTV or RYM more profitable?

Do analysts recommend PSTV or RYM?

Do insiders and institutionals have more ownership in PSTV or RYM?

Does the media favor PSTV or RYM?

Which has better earnings & valuation, PSTV or RYM?

Which has more volatility and risk, PSTV or RYM?

Summary

How does Plus Therapeutics compare to Dogwood Therapeutics?

Which has stronger valuation and earnings, PSTV or DWTX?

Does the media refer more to PSTV or DWTX?

Is PSTV or DWTX more profitable?

Which has more risk and volatility, PSTV or DWTX?

Do analysts rate PSTV or DWTX?

Do insiders and institutionals believe in PSTV or DWTX?

Summary

How does Plus Therapeutics compare to Grace Therapeutics?

Is GRCE or PSTV more profitable?

Which has preferable earnings & valuation, GRCE or PSTV?

Which has more volatility and risk, GRCE or PSTV?

Do insiders and institutionals have more ownership in GRCE or PSTV?

Do analysts prefer GRCE or PSTV?

Does the media refer more to GRCE or PSTV?

Summary

How does Plus Therapeutics compare to SCYNEXIS?

Does the media favor SCYX or PSTV?

Do insiders & institutionals believe in SCYX or PSTV?

Which has more volatility & risk, SCYX or PSTV?

Do analysts rate SCYX or PSTV?

Which has higher earnings and valuation, SCYX or PSTV?

Is SCYX or PSTV more profitable?

Summary

How does Plus Therapeutics compare to Agrify?

Which has more volatility & risk, AGFY or PSTV?

Does the media prefer AGFY or PSTV?

Do insiders & institutionals believe in AGFY or PSTV?

Is AGFY or PSTV more profitable?

Do analysts recommend AGFY or PSTV?

Which has better earnings & valuation, AGFY or PSTV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTV vs. The Competition

Plus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools